Fig 1: TRPC3/6 agonist and antagonist have no effect on calcium signaling in human mast cells. Calcium imaging of Fura 2-AM loaded HEK-TRPC6. (A) Concentration-response curve in HEK-TRPC6 cells – summarizing change in calcium signal to varying concentrations of GSK-2934A agonist. (B) Effect of varying concentrations of antagonist GSK-3503A to 3 µmol/L GSK-2934A induced calcium signal in HEK-TRPC6 cells. n > 20 cells for each concentration performed over 2-3 independent experiments. Data shown as mean ± SEM (C-F) Calcium imaging of fura 2-AM loaded HLMCs. (C) Calcium signal over time; DMSO vehicle control/3 µmol/L GSK-2934A was applied as indicated by the horizontal bars, followed by anti-IgE, 1 µg/mL. (D) Scatter graph showing max-basal calcium signal of TRPC3/6 agonist (before anti-IgE application) (E) Calcium signal over time. Effect of GSK-3503A on anti-IgE induced calcium entry. Solutions applied as indicated by horizontal bars. 2 µmol/L GSK-3503A pre-incubated for 10 min and present in solution throughout the experimental duration. (F) Scatter graph showing max-basal calcium signal of anti-IgE response in each cell. Lines in bar graphs show mean ± SEM, calcium signal over time show representative traces. n > 45 cells for each condition, N = 3 donors. Results were analyzed, using unpaired students t-test, ns P > 0.05.